Conversion of Recent-Onset Atrial Fibrillation with Intravenous Amiodarone: A Meta-Analysis of Randomized Controlled Trials

• Published in: Pharmacotherapy 2002-01, Vol.22 (1), p.66-74
• Main Authors: Hilleman, Daniel E., Spinler, Sarah A.
• Format: Article
• Language: English
• Subjects: Amiodarone; Amiodarone - adverse effects; Amiodarone - therapeutic use; Anti-Arrhythmia Agents - adverse effects; Anti-Arrhythmia Agents - therapeutic use; Antiarythmic agents; Atrial Fibrillation - drug therapy; Biological and medical sciences; Bradycardia - chemically induced; Cardiovascular system; Cohort Studies; Humans; Hypotension - chemically induced; Injections, Intravenous; Medical sciences; Pharmacology. Drug treatments; Phlebitis - chemically induced; Randomized Controlled Trials as Topic
• ISSN: 0277-0008; 1875-9114
• DOI: 10.1592/phco.22.1.66.33492

Study Objective. To evaluate efficacy and safety of intravenous amiodarone for conversion of recent‐onset atrial fibrillation. Data Sources. MEDLINE search of published, randomized, controlled trials assessing the efficacy and safety of intravenous amiodarone in recent‐onset (< 7 days) atrial fibrillation, supplemented with searches of reference lists of identified articles and bibliographies of secondary and tertiary review articles. Study Selection. The identified trials were eligible for meta‐analysis if they met the following criteria: patients had recent‐onset atrial fibrillation; patients were randomized to intravenous amiodarone, placebo, or another antiarrhythmic agent; no other antiarrhythmic agent except digoxin was administered simultaneously with intravenous amiodarone or other active treatments; the number and percentage of conversions to sinus rhythm after treatment began were reported; and the number and type of adverse drug reactions occurring after treatment began were reported. Results. Eighteen randomized controlled trials, including active control cohorts and placebo cohorts, met inclusion criteria. Atrial fibrillation was spontaneous in 13 trials, postoperative in 4, and combined spontaneous and postoperative in 1. A total of 550 patients received intravenous amiodarone, 451 received other antiarrhythmic therapy, and 202 received placebo. Unadjusted averages for cardioversion were as follows: intravenous amiodarone, 417 (76%) of 550 patients; other antiarrhythmics, 324 (72%) of 451 patients; and placebo, 121 (60%) of 202 patients. Pooled estimates of cardioversion for active cohort studies were 72.1% for intravenous amiodarone and 71.9% for other antiarrhythmics (p=0.84). Pooled estimates of cardioversion for placebo cohort studies were 82.4% for intravenous amiodarone and 59.7% for placebo (p=0.03). Unadjusted averages for adverse event rates were intravenous amiodarone, 94 (17%) of 550 patients; other antiarrhythmics, 63 (14%) of 451 patients; and placebo, 23 (11%) of 202 patients. Pooled estimates of adverse event rates for active cohort studies were 12.2% for intravenous amiodarone and 14.0% for other antiarrhythmics (p=0.64). Pooled estimates of adverse event rates for placebo cohort studies were 26.8% for intravenous amiodarone and 10.8% for placebo (p=0.02). The most common adverse drug reactions reported with intravenous amiodarone were infusion phlebitis, bradycardia, and hypotension. Conclusion. The efficacy and safety profil